Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

GT Biopharma (OXI) Stock Price & Analysis

0 Followers

OXI Stock Chart & Stats

€119.25€0.00(0.00%)
At close: 5:30 PM GMT+1
€500€1KOct 14Feb 15Feb 28Jun 20Jun 29Sep 18Feb 2
Day’s Range
EUR 119.25 - EUR 119.25
52-Week Range
EUR 119.25 - EUR 140.25
Previous Close
EUR 119.25
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 7.31M
Enterprise Value
EUR 13.96M
Total Cash (Recent Filing)
EUR 4.96M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.00
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
-2.24
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Immuno-oncology Pipeline

The company is focused on engineered immune-cell–engaging biologics, giving it a specialized platform centered on directing immune responses against cancer. If development succeeds, the approach could support multiple indications and create longer-term pipeline leverage beyond a single product.

Debt-free Balance Sheet

Zero reported debt reduces interest expense and refinancing pressure, preserving more flexibility while the company funds research and development. This provides a structural financial advantage relative to leveraged peers, although it does not eliminate the need to secure operating capital.

Expanded Financing Access

The expanded Series M financing provides additional capital access for a pre-commercial biotechnology business and includes registration rights that may improve investor liquidity. Greater funding capacity can help sustain development activities over the next several months, despite associated security complexity.

Bears Say

Pre-revenue And Unprofitable

The absence of revenue means the company has not yet demonstrated commercial traction or an operating model that funds itself. Large recurring losses leave results dependent on future clinical and commercialization progress, making earnings improvement difficult to establish over the medium term.

Accelerating Cash Burn

Persistent and worsening negative cash flow indicates that operations consume substantial funding rather than generate it. Continued development therefore depends on external capital, while a higher burn rate can shorten financial runway and increase the importance of future financing execution.

Shrinking Equity Cushion

Contracting assets and a thin, volatile equity base reduce financial flexibility even without debt. A smaller balance-sheet cushion leaves less capacity to absorb setbacks or sustain investment internally, increasing reliance on new equity financing and potentially weakening existing holders’ position.

GT Biopharma News

OXI FAQ

What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was €119.25 and its highest was €140.25 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is €7.31M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is today.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Aug 14, 2026. The company reported -€2.686 earnings per share for the quarter, missing the consensus estimate of -€1.791 by -€0.895.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -2.24.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 2,061,052 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -€2.686 in its last earnings report, missing expectations of -€1.791. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GT Biopharma?
Hedge funds hold GT Biopharma shares: hedge funds decreased their holdings by 23.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology